Stockreport

Dosing underway in mid-stage study of Paratek's omadacycline in type of urinary tract infection [Seeking Alpha]

Paratek Pharmaceuticals, Inc.  (PRTK) 
Last paratek pharmaceuticals, inc. earnings: 2/25 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.paratekpharma.com
PDF The first patient has been dosed in a Phase 2 clinical trial evaluating Paratek Pharmaceuticals' ( PRTK ) oral and IV omadacycline, branded as NUZYRA, in patie [Read more]